X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs GLENMARK PHARMA - Comparison Results

WOCKHARDT    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT GLENMARK PHARMA WOCKHARDT/
GLENMARK PHARMA
 
P/E (TTM) x -14.0 19.1 - View Chart
P/BV x 1.7 3.4 49.0% View Chart
Dividend Yield % 0.0 0.3 0.7%  

Financials

 WOCKHARDT   GLENMARK PHARMA
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
GLENMARK PHARMA
Mar-18
WOCKHARDT/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,012930 108.8%   
Low Rs532517 102.7%   
Sales per share (Unadj.) Rs355.9322.6 110.3%  
Earnings per share (Unadj.) Rs-60.328.5 -211.6%  
Cash flow per share (Unadj.) Rs-46.839.2 -119.3%  
Dividends per share (Unadj.) Rs0.012.00 0.5%  
Dividend yield (eoy) %00.3 0.5%  
Book value per share (Unadj.) Rs257.8183.0 140.9%  
Shares outstanding (eoy) m110.63282.17 39.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.2 96.7%   
Avg P/E ratio x-12.825.4 -50.4%  
P/CF ratio (eoy) x-16.518.5 -89.4%  
Price / Book Value ratio x3.04.0 75.7%  
Dividend payout %07.0 -0.2%   
Avg Mkt Cap Rs m85,379204,206 41.8%   
No. of employees `0006.313.7 45.6%   
Total wages/salary Rs m9,37118,718 50.1%   
Avg. sales/employee Rs Th6,295.06,636.8 94.8%   
Avg. wages/employee Rs Th1,498.31,364.7 109.8%   
Avg. net profit/employee Rs Th-1,066.3586.1 -181.9%   
INCOME DATA
Net Sales Rs m39,36991,031 43.2%  
Other income Rs m1,202914 131.5%   
Total revenues Rs m40,57191,945 44.1%   
Gross profit Rs m1816,154 0.1%  
Depreciation Rs m1,4953,019 49.5%   
Interest Rs m2,5552,856 89.5%   
Profit before tax Rs m-2,83011,193 -25.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m2573,155 8.1%   
Profit after tax Rs m-6,6698,039 -83.0%  
Gross profit margin %017.7 0.3%  
Effective tax rate %-9.128.2 -32.2%   
Net profit margin %-16.98.8 -191.8%  
BALANCE SHEET DATA
Current assets Rs m33,79669,887 48.4%   
Current liabilities Rs m26,91732,879 81.9%   
Net working cap to sales %17.540.7 43.0%  
Current ratio x1.32.1 59.1%  
Inventory Days Days7981 97.4%  
Debtors Days Days8993 95.4%  
Net fixed assets Rs m39,66428,892 137.3%   
Share capital Rs m553282 196.0%   
"Free" reserves Rs m27,96851,353 54.5%   
Net worth Rs m28,52251,635 55.2%   
Long term debt Rs m21,73141,418 52.5%   
Total assets Rs m81,620125,954 64.8%  
Interest coverage x-0.14.9 -2.2%   
Debt to equity ratio x0.80.8 95.0%  
Sales to assets ratio x0.50.7 66.7%   
Return on assets %-5.08.6 -58.3%  
Return on equity %-23.415.6 -150.2%  
Return on capital %-7.715.1 -50.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80736,317 27.0%   
Fx outflow Rs m1,7899,720 18.4%   
Net fx Rs m8,01926,598 30.1%   
CASH FLOW
From Operations Rs m68416,481 4.2%  
From Investments Rs m6,302-10,133 -62.2%  
From Financial Activity Rs m-7,695-4,685 164.2%  
Net Cashflow Rs m-6641,770 -37.5%  

Share Holding

Indian Promoters % 74.5 48.3 154.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 6.9 33.3%  
FIIs % 7.7 34.4 22.4%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 10.5 146.7%  
Shareholders   67,757 56,727 119.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   J.B.CHEMICALS  ALEMBIC LTD  CIPLA  AJANTA PHARMA  SUVEN LIFESCIENCES  

Compare WOCKHARDT With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Uptrend, Jet Airways in Focus and Other Top Stocks in Action Today(Pre-Open)

On Monday, share markets in India opened on a positive note and ended the day in green after a volatile day of trading.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Mar 18, 2019 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT 8-QTR ANALYSIS

COMPARE WOCKHARDT WITH

MARKET STATS